Neurometrix Stock Today
| NURO Stock | USD 4.25 0.03 0.71% |
Performance5 of 100
| Odds Of DistressLess than 15
|
NeuroMetrix is selling at 4.25 as of the 26th of November 2024; that is 0.71 percent increase since the beginning of the trading day. The stock's open price was 4.22. NeuroMetrix has less than a 15 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for NeuroMetrix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of September 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 2nd of January 2001 | Category Healthcare | Classification Health Care |
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has 2.04 M outstanding shares of which 15.78 K shares are now shorted by private and institutional investors with about 1.12 trading days to cover. More on NeuroMetrix
Moving against NeuroMetrix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NeuroMetrix Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNeuroMetrix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NeuroMetrix's financial leverage. It provides some insight into what part of NeuroMetrix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NeuroMetrix (NURO) is traded on NASDAQ Exchange in USA. It is located in 4B Gill Street, Woburn, MA, United States, 01801 and employs 26 people. NeuroMetrix is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.62 M. NeuroMetrix conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 2.04 M outstanding shares of which 15.78 K shares are now shorted by private and institutional investors with about 1.12 trading days to cover.
NeuroMetrix currently holds about 20.83 M in cash with (6.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68.
Check NeuroMetrix Probability Of Bankruptcy
Ownership AllocationNeuroMetrix holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check NeuroMetrix Ownership Details
NeuroMetrix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Ubs Group Ag | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 | |
| Corecap Advisors, Llc | 2024-06-30 | 0.0 | |
| Vanguard Group Inc | 2024-09-30 | 15.1 K | |
| Geode Capital Management, Llc | 2024-09-30 | 13.8 K | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 6.7 K | |
| Blackrock Inc | 2024-06-30 | 5 K | |
| Tower Research Capital Llc | 2024-06-30 | 1.7 K | |
| Tucker Asset Management Llc | 2024-06-30 | 402 | |
| Accent Capital Management Llc | 2024-09-30 | 300 |
NeuroMetrix Historical Income Statement
NeuroMetrix Stock Against Markets
NeuroMetrix Corporate Executives
Elected by the shareholders, the NeuroMetrix's board of directors comprises two types of representatives: NeuroMetrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuroMetrix. The board's role is to monitor NeuroMetrix's management team and ensure that shareholders' interests are well served. NeuroMetrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuroMetrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Higgins | CFO, Principal Accounting Officer, Sr. VP and Treasurer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.51) | Revenue Per Share 2.157 | Quarterly Revenue Growth (0.51) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.